echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Early experience in the treatment of malignant gliomas by proton heavy ion particles.

    Early experience in the treatment of malignant gliomas by proton heavy ion particles.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Malignant high-level gliomas (high-grade gliomas, HGG), including polymorphic glioma multiforme, GBM, and interstitial astrocytoma (anaplastic astrocytoma, AA), diffusely impregnated growth, progression, can not be completely removed. Although after
    , the recurrence rate was very high, although high-dose radiotherapy.
    the application of new radiotherapy techniques, such as dose increase, multi-level radiotherapy and increased stereotactic radiation therapy, but has not yet formed a standardized standard of radiation therapy.
    slightly improved overall survival rate (OS) after combination with the treatment of promozola, especially in patients with MGMT promoter methylation.
    in general, patients with medium survival remained short,
    , and the OS rates of high-level gliomas were also not significantly improved.
    proton heavy ions have superior physical properties, as well as a higher linear energy transfer (LET) effect, which can directly cause significant damage to tumor cells through the double strands of DNA.
    Lin Kong of the Shanghai Proton Heavy Ion Center and others report on the results of a group of proton heavy ion particles in the 2020 journal Cancer.

    research methods
    between June 2015 and October 2018, 50 patients with HGG were treated at the Shanghai Proton Heavy Ion Center, of which 34 were GBM and 16 cases of AA.
    24 cases received proton radiotherapy, 60Gy/30d, and 26 cases received proton-carbon ion radiotherapy (CIRT), each using a different dose increment scheme.
    all patients treated with a combination of submethylation based on age or MGMT.

    50 patients followed up for 4.8-39.6 months after proton reion radiation therapy, with a median follow-up time of 14.3 months. the OS rates for the 12 and 18 months of
    were 87.8% (95% CI, 77.6%-98.0%) and 72.8% (95% CI, 56.7%-88.9%), respectively; The Non-ProgressLess Survival (PFS) rates were 74.2% (95% CI, 60.9%-87.5%) and 59.8% (95% CI, 43.1%-76.5%) respectively (Figure 1). The 12-month and 18-month OS rates were 77.4% and 61% respectively for patients with
    HGG, and 61.3% and 42.7% respectively.
    and WHO Grade III tumor patients had 100% OS and PFS rates for 12 and 18 months.
    Figure 1. The total lifetime (A) and no progression survival (B) curves of HGG patients after proton heavy ion therapy.

    results
    follow-up results after radiotherapy found significant local necrosis or progression in 12 patients' particle radiotherapy areas.
    3 patients with the recurrence of tumors outside the radiation treatment area, but none of them had recurrence sours of the limbic tumor in the radiation treatment area.
    1 patient was diagnosed with disease progression on MRI imaging 6 months after particle radiation therapy, and then surgically removed, and a pathological examination confirmed the false progression.

    29 patients developed level 1 dermatitis or hair loss during particle radiotherapy.
    seven cases of false progression, followed by a decline or pathological confirmation of the false progression.
    in addition, 6 cases of advanced radionesic necrosis of level 1 and 5 of 2 occurred in 11 patients, while no acute or late-stage radioactive toxicreactions of level s3, 4 and 5 were observed.
    single-variable log-rank test analysis shows that age (?50: 50 years old), WHO grading (3:4) and Karnofsky score (-80:80) are significant factors in predicting OS rates.
    IDH mutants and WHO grading are significant in predicting PFS.
    in addition, MGMT initiation submethylation, functional status, and age have trends in predicting PFS.
    multivariate analysis did not find significant factors predicting PFS or OS.

    Conclusion Finally, the authors point out that the 18-month OS rate and PFS rate were 72.8% and 59.8% in patients with HGG treatment with a dose of 60Gyin in combination with dymomine, respectively;
    , proton heavy ion particle radiotherapy is a safe and potentially effective means of treating high-level gliomas.
    Copyright Notice The copyright of works published by the God's Outer Information APP, including but not limited to the copyright of text, pictures and videos, is owned by the organizer/original author and divinated information, and no one may steal any content by direct or indirect means such as adaptation, tailoring, reproduction, reproduction, reproduction, recording, etc. without the express authorization of outside information.
    works authorized by outside god information should be used within the scope of authorization, please indicate the source: god information.
    if there is a violation, the outside information will reserve the right to further pursue the infringement of legal liability.
    outside the gods welcomeindividuals to forward and share works published under this number.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.